ArticleScientific reports2024
Unraveling the therapeutic potential of quercetin and quercetin-3-O-glucuronide in Alzheimer's disease through network pharmacology, molecular docking, and dynamic simulations.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Silver doping induced fluorescence enhancement of gold nanoclusters combined with machine learning for detection of quercetin.Analytical and bioanalytical chemistry · 2026Article
- Quercetin as a Multifunctional Flavonol: Molecular Insights and Therapeutic Applications.Molecules (Basel, Switzerland) · 2026Review
- Plant-mediated green nanoparticles: combining nanometal and biometabolite potential for Alzheimer's treatment.Biomedical engineering online · 2026Review
- Multi-Method Screening of Commercial Antioxidant Supplements: Antioxidant Activity and Selected Antioxidant Compound Profiles.Foods (Basel, Switzerland) · 2026Article
- Wine-Processed Cornus officinalis Ameliorates Osteoarthritis via Modulating M1/M2 Macrophage Polarization.Journal of cellular and molecular medicine · 2026Article
- Unrevealing possible mechanism of Riluzole, Salsalate and Nimodipine in Alzheimer's disease: multi-target network pharmacological perspective.Inflammopharmacology · 2026Article
- Engineered Novel Brijaluronic Terpesomes for Brain-Targeted Quercetin Delivery: Optimization, Ex Vivo and Radiokinetics.AAPS PharmSciTech · 2026Article
- Toll-Like Receptors in Diabetes: Immunometabolic Mechanisms and Emerging Precision Therapeutic Strategies.Journal of inflammation research · 2026Review
- Deciphering the Multi-Target Therapeutic Mechanisms of Traditional Chinese Medicine Against Alzheimer's Disease: A Network Pharmacology Perspective.Drug design, development and therapy · 2026Review
- Therapeutic effects of Gancao Xiexin Decoction on renal ischemia-reperfusion injury based on network pharmacology and experimental validation.BMC nephrology · 2025Article
- Article
- Natural drug delivery systems for the treatment of neurodegenerative diseases.Molecular biology reports · 2025Review
- Sequential Obtention of Blood-Brain Barrier-Permeable Non-Polar and Polar Compounds fromInternational journal of molecular sciences · 2025Article
- Pharmacological Insights and Therapeutic Applications of Leonurus in Neurological Disorders.Journal of inflammation research · 2025Review
- Exploring the Neuroprotective Potentials of Flavonoid Metabolites inJournal of experimental pharmacology · 2025Review
- Enhanced Bioactivity of Quercetin-Tetrahydroisoquinoline Derivatives: Effect on Lipophilicity, Enzymes Inhibition, Antioxidant Potential, and Cytotoxicity.International journal of molecular sciences · 2024Article
- Review
- Antimigraine activity of Asarinin by OPRM1 pathway with multifaceted impacts through network analysis.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin is a flavonoid with notable pharmacological effects and promising therapeutic potential. Quercetin plays a significant role in neuroinflammation, which helps reduce Alzheimer's disease (AD) severity. Quercetin (Q) and quercetin 3-O-glucuronide (Q3OG) are some of the most potent antioxidants available from natural sources. However, the natural form of quercetin converted into Q3OG when reacted with intestinal microbes. The study aims to ensure the therapeutic potential of Q and Q3OG. In this study, potential molecular targets of Q and Q3OG were first identified using the Swiss Target Prediction platform and pathogenic targets of AD were identified using the DisGeNET database. Followed by compound and disease target overlapping, 77 targets were placed in that AKT1, EGFR, MMP9, TNF, PTGS2, MMP2, IGF1R, MCL1, MET and PARP1 was the top-ranked target, which was estimated by CytoHubba plug-in. The Molecular docking was performed for Q and Q3OG towards the PDB:1UNQ target. The binding score of Q and Q3OG was - 6.2 kcal/mol and - 6.58 kcal/mol respectively. Molecular dynamics simulation was conducted for Q and Q3OG towards the PDB:1UNQ target at 200 ns. This study's results help identify the multiple target sites for the bioactive compounds. Thus, synthesizing new chemical entity-based quercetin on structural modification may aid in eradicating AD complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.